These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35836542)

  • 1. EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report.
    Zhang Z; Liu N; Li Q
    Transl Cancer Res; 2022 Jun; 11(6):1829-1835. PubMed ID: 35836542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma.
    Weng Y; Wang L; Wang XY; Fan XX; Yan L; Li ZH; Zhang SL
    Front Endocrinol (Lausanne); 2023; 14():1115893. PubMed ID: 37745701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
    Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
    Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience.
    Laganà M; Grisanti S; Cosentini D; Ferrari VD; Lazzari B; Ambrosini R; Sardini C; Volta AD; Palumbo C; Poliani PL; Terzolo M; Sigala S; Tiberio GAM; Berruti A
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
    Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
    Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status.
    Turla A; Laganà M; Abate A; Cremaschi V; Zamparini M; Chittò M; Consoli F; Alberti A; Ambrosini R; Tamburello M; Grisanti S; Tiberio GAM; Sigala S; Cosentini D; Berruti A
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy in advanced adrenocortical carcinoma.
    Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
    N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen.
    Turla A; Laganà M; Grisanti S; Abate A; Ferrari VD; Cremaschi V; Sigala S; Consoli F; Cosentini D; Berruti A
    Endocrine; 2022 Sep; 77(3):438-443. PubMed ID: 35567656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
    Sasaki S
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
    Laganà M; Grisanti S; Ambrosini R; Cosentini D; Abate A; Zamparini M; Ferrari VD; Gianoncelli A; Turla A; Canu L; Terzolo M; Tiberio GAM; Sigala S; Berruti A
    ESMO Open; 2022 Apr; 7(2):100422. PubMed ID: 35272132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenocortical tumors in children.
    Ciftci AO; Senocak ME; Tanyel FC; Büyükpamukçu N
    J Pediatr Surg; 2001 Apr; 36(4):549-54. PubMed ID: 11283875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term partial response in a patient with liver metastasis of primary adrenocortical carcinoma with adjuvant mitotane plus transcatheter arterial chemoembolization and microwave ablation: a case report.
    Deng J; Wei L; Fan Q; Wu Z; Ji Z
    Front Oncol; 2023; 13():1157740. PubMed ID: 37313469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma.
    Shetty I; Fuller S; Raygada M; Merino MJ; Thomas BJ; Widemann BC; Reilly KM; Pacak K; Del Rivero J
    Endocrinol Diabetes Metab Case Rep; 2020 Jan; 2020():. PubMed ID: 31917677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Aggressive Case of Adrenocortical Carcinoma Complicated by Paraneoplastic Cushing's Syndrome.
    Mohamed Jiffry MZ; Hernandez B; Josephs M; Khan A; Malik Z
    Cureus; 2023 Jan; 15(1):e34099. PubMed ID: 36843704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.
    Roca E; Berruti A; Sbiera S; Rapa I; Oneda E; Sperone P; Ronchi CL; Ferrari L; Grisanti S; Germano A; Zaggia B; Scagliotti GV; Fassnacht M; Volante M; Terzolo M; Papotti M
    Endocr Relat Cancer; 2017 Jul; 24(7):319-327. PubMed ID: 28432084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival in recurrent adrenocortical cancer.
    Shuayb M; Das A; Uddin MN
    BMJ Support Palliat Care; 2019 Mar; 9(1):47-50. PubMed ID: 29903850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Embolism as an Initial Presentation of Adrenocortical Carcinoma.
    Aung SY; Parente P; McKendrick J
    World J Oncol; 2014 Jun; 5(3):149-152. PubMed ID: 29147395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.